Cancer types
  • Lung
Title of study
Phase II study examining the activity of L19-IL2 immunotherapy and (stereotactic ablative) radiotherapy in metastatic non-small cell lung cancer
Version Number
Approval Date 
3.0, 4 October 2019
Short Title
Study site
Principle Investigator
Prof. Dr.Philippe Lambin, Dr. Lizza Hendriks
Investigator Maastro
D. De Ruysscher
Maastricht University
Trial registry
Primary Endpoint 

Primary endpoint is progression free survival at 1.5 years after randomization

Secondary Endpoints 

• Overall survival
• Quality of life
• Abscopal responses defined as partial or complete remission to RECIST 1.1 of lesions outside the radiotherapy field
• Associative biomarkers
• Determination of hypoxia status by [18F]HX4-Positron Emmission Tomography (PET)